India, June 3 -- Evotec SE (EVO) announced that shareholders approved the majority of management's proposals at its 2025 Annual General Meeting, held under the theme "Pioneering Drug Discovery."
The meeting was chaired by Prof. Dr. Iris Low-Friedrich, Chairperson of the Supervisory Board. CEO Dr. Christian Wojczewski presented strategic, scientific, and business updates, reaffirming Evotec's commitment to sustainable growth. Newly appointed board members Aurelie Dalbiez (Chief People Officer) and Paul Hitchin (Chief Financial Officer) also addressed shareholders.
Key decisions passed by a large majority included discharging board members of liability for the 2024 financial year and approving the 2024 Remuneration Report. Shareholders also...